Innate Pharma
Clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system.
Launch date
Employees
Market cap
AUD292m
Enterprise valuation
AUD196m (Public information from Sep 2024)
Share price
$2.25 IPHA
Company register number 424365336
Marseille Provence-Alpes-Côte d'Azur (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 33.6m | 85.8m | 69.0m | 56.8m | 12.1m | 49.6m | 51.9m |
| % growth | (52 %) | 155 % | (20 %) | (18 %) | (79 %) | 310 % | 5 % |
| EBITDA | (44.8m) | 11.0m | (8.9m) | 43.1m | (36.9m) | 33.8m | (4.4m) |
| % EBITDA margin | (133 %) | 13 % | (13 %) | 76 % | (305 %) | 68 % | (8 %) |
| Profit | (49.8m) | 3.3m | (20.8m) | (64.0m) | (52.8m) | (58.1m) | (7.6m) |
| % profit margin | (148 %) | 4 % | (30 %) | (113 %) | (436 %) | (117 %) | (15 %) |
| R&D budget | 3.3m | 74.7m | 1.6m | 58.6m | 47.0m | 51.7m | 56.0m |
| R&D % of revenue | 10 % | 87 % | 2 % | 103 % | 388 % | 104 % | 108 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€4.5m | Series A | ||
€20.0m | Series B | ||
€15.0m | Series C | ||
€20.3m | Post IPO Equity | ||
€50.0m | Post IPO Equity | ||
| N/A | N/A | IPO | |
| N/A | €62.6m Valuation: €639m 7.5x EV/LTM Revenues 58.2x EV/LTM EBITDA | Post IPO Equity | |
* | N/A | $75.0m | POST IPO SECONDARY |
| Total Funding | AUD67.2m | ||
Recent News about Innate Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.